$FLGTBearishLow

Xie Jian sold $38K of FLGT

Xie Jian (President and COO) sold 2,146 shares of Fulgent Genetics, Inc. (FLGT) at $17.89 on 2026-06-02.

6/10
6/10
Low
Bearish
Filed June 3; sale executed June 2 (post-close disclosure window).
Neutral-to-slightly negative (insider selling).

Insider selling is a modest negative signal, but this specific Form 4 provides limited fundamental information without a 10b5-1 plan or stated reason.

Fulgent Genetics’ President/COO Xie Jian sold 2,146 shares in an open-market transaction disclosed via SEC Form 4 on June 2.

Likely small, short-lived impact at most; more relevant for monitoring than for a standalone trade.

Background

This is an SEC Form 4 insider transaction: an officer (President and COO) reported an open-market sale of FLGT shares.

Why it matters

Traders may use insider activity as a sentiment/positioning input, but it is not a substitute for fundamental catalysts. The lack of a stated 10b5-1 plan can raise attention, yet insider sales remain common and often non-predictive without corroborating news.

Market relevance

A single insider sale at a disclosed price; potential mild negative sentiment but no clear fundamental trigger.

Market effects

Limited read-across to biotech broadly; this is company-specific insider activity.

None indicated.

None indicated.

Alternative perspectives

The sale could be routine liquidity/portfolio management; without additional context, it may not reflect business outlook.

No stated reason for the sale, and the filing does not confirm whether other planned sales or compensation-related events are occurring.

Key entities

  • Fulgent Genetics, Inc.

    Biopharma company whose officer disclosed an open-market insider sale via SEC Form 4.

  • Xie Jian

    President and COO who sold 2,146 shares at $17.8855 on 2026-06-02.

Related articles

$FLGTMed

Fulgent Genetics infertility test panels broaden to cover over 140 genes for females and 160 for males

Fulgent Genetics has significantly expanded its infertility next-generation sequencing (NGS) panels, now covering 143 genes for females and 163 genes for males. The company recommends combining these expanded panels with BeaconCarrierScreening for a thorough reproductive health assessment. This enhancement aims to provide more comprehensive genetic insights for couples facing fertility challenges.

$FLGTLow

Fulgent Genetics (FLGT) CFO has 2,747 shares withheld for RSU taxes

Fulgent Genetics' CFO and Treasurer, Paul Kim, had 2,747 shares of common stock withheld on April 26, 2026, to cover tax obligations arising from the vesting of restricted stock units. This was a routine tax-related disposition, not an open-market sale, and the shares were valued at $16.31 each. Following this transaction, Kim continues to hold a substantial 365,800 shares of Fulgent common stock.

$FLGTLow

Fulgent Genetics (FLGT) COO reports tax-withholding share disposition after RSU vesting

Jian Xie, President and COO of Fulgent Genetics (FLGT), reported a routine tax-related disposition of 4,361 common shares at $16.31 per share. This withholding was to satisfy tax obligations arising from the vesting of restricted stock units (RSUs) assumed through a prior merger. Following this transaction, Xie directly holds 370,952 common shares, with an additional 220,816 shares held indirectly by The Hsieh Family Dynasty Trust.

$FLGTMed

Fulgent Genetics (FLGT) to Acquire Assets from Bako Diagnostics and StrataDx

Fulgent Genetics (FLGT) plans to acquire assets from Bako Diagnostics and StrataDx for approximately $55.5 million, using existing cash reserves. This strategic move, expected to finalize in the first half of 2026, aims to enhance Fulgent's diagnostic capabilities and expand its laboratory network. Despite financial challenges like declining revenue growth and insider selling, the company maintains strong financial health and liquidity, though investors are advised to exercise caution.